Aura Biosciences Announces Participation at Upcoming Investor Conferences

CAMBRIDGE, Mass.--()--Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that members of Aura’s executive team will participate in the following upcoming investor conferences:

  • Canaccord Genuity’s 39th Annual Growth Conference on August 8, 2019 in Boston, MA and will present at 2:00 p.m. Eastern Time
  • BTIG Biotechnology Conference on August 12, 2019 in New York, NY

About Aura Biosciences

Aura Biosciences is developing a new class of therapies to selectively target and destroy cancer cells. Its lead program, AU-011 for the treatment of primary choroidal melanoma, is being developed under a CRADA with the National Cancer Institute (NCI), part of the National Institutes of Health. For more information, visit www.aurabiosciences.com.

Contacts

Media:
David Rosen
Argot Partners
212.600.1902 | david.rosen@argotpartners.com

Investors:
Joseph Rayne
Argot Partners
617.340.6075 | joseph@argotpartners.com

Contacts

Media:
David Rosen
Argot Partners
212.600.1902 | david.rosen@argotpartners.com

Investors:
Joseph Rayne
Argot Partners
617.340.6075 | joseph@argotpartners.com